| Title |
A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, January 2018
|
| DOI | 10.1007/s00262-018-2116-1 |
| Pubmed ID | |
| Authors |
Joseph M. Ryan, Payal Mittal, Antoine Menoret, Julia Svedova, Jeffrey S. Wasser, Adam J. Adler, Anthony T. Vella |
| Abstract |
Combination immunotherapies utilizing complementary modalities that target distinct tumor attributes or immunosuppressive mechanisms, or engage different arms of the antitumor immune response, can elicit greater therapeutic efficacy than the component monotherapies. Increasing the number of agents included in a therapeutic cocktail can further increase efficacy, however, this approach poses numerous challenges for clinical translation. Here, a novel platform to simplify combination immunotherapy by covalently linking immunotherapeutic agonists to the costimulatory receptors CD134 and CD137 into a single heterodimeric drug, "OrthomAb", is shown. This reagent not only retains costimulatory T cell activity, but also elicits unique T cell functions that are not programmed by either individual agonist, and preferentially expands effector T cells over Tregs. Finally, in an aggressive melanoma model OrthomAb elicits better therapeutic efficacy compared to the unlinked agonists. This demonstration that two drugs can be combined into one provides a framework for distilling complex combination drug cocktails into simpler delivery platforms. |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 43% |
| Other | 3 | 11% |
| Student > Doctoral Student | 3 | 11% |
| Unspecified | 1 | 4% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 9 | 32% |
| Agricultural and Biological Sciences | 3 | 11% |
| Engineering | 3 | 11% |
| Computer Science | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 7 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2023.
All research outputs
#4,909,804
of 23,592,647 outputs
Outputs from Cancer Immunology, Immunotherapy
#515
of 2,882 outputs
Outputs of similar age
#106,100
of 445,747 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#3
of 31 outputs
Altmetric has tracked 23,592,647 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,882 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,747 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.